Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Faron Pharmaceuticals Oy

FARN
Current price
154.9 GBX +2.41 GBX (+1.57%)
Last closed 152.5 GBX
ISIN FI4000153309
Sector Healthcare
Industry Biotechnology
Exchange London Exchange
Capitalization 173 130 416 GBX
Yield for 12 month -42.63 %
1Y
3Y
5Y
10Y
15Y
FARN
21.11.2021 - 28.11.2021

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland. Address: Joukahaisenkatu 6 B, Turku, Finland, 20520

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

244.63 GBX

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures FARN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -26 942 688 GBX
Operating Margin TTM
PE Ratio
Return On Assets TTM -70 %
PEG Ratio
Return On Equity TTM -3961.5 %
Wall Street Target Price 244.63 GBX
Revenue TTM 805 322 GBX
Book Value 0.013 GBX
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -86.9 %
Dividend Yield
Gross Profit TTM 805 322 GBX
Earnings per share -0.32 GBX
Diluted Eps TTM -0.32 GBX
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics FARN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FARN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 5000:4999
Payout Ratio
Last Split Date 07.08.2019
Dividend Date

Stock Valuation FARN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 16.209
Enterprise Value EBITDA -3.5272
Price Book MRQ 148.3365

Financials FARN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators FARN

For 52 weeks

85.25 GBX 371.07 GBX
50 Day MA 209.13 GBX
Shares Short Prior Month
200 Day MA 172.41 GBX
Short Ratio
Shares Short
Short Percent